Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

Completed · Phase 2

Conditions studied: Pterygium

In brief

This study will evaluate the safety and efficacy of Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®) in patients with primary pterygium (abnormal growth on surface of eye).

Key facts

Study ID

NCT01109056

Run by

Allergan

People needed

115

Starts

2010-06-01

Expected to finish

2011-06-01

Last updated by the study team

2012-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a pterygium in at least one eye that has not been previously removed with surgery

You may not qualify if…

• Uncontrolled systemic disease
• Active eye disease
• Current or anticipated use of topical eye medications other than artificial tears.
• Anticipated wearing of contact lenses

Where it is running

• Study site — Glendale, California, United States
• Study site — Randwick, New South Wales, Australia
• Study site — Singapore, Singapore

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.